Last reviewed · How we verify

NCT05714579: TAVHIS

Predictive Value of Pre-TAVI Infrahissian Conduction Time in the Occurrence of Complete Atrioventricular Block

Terminated NA Last updated 25 March 2025
What this trial tests

NA trial testing Transcatheter Aortic Valve Implantation in Aortic Stenosis, Severe in 35 participants. Terminated before completion.

Timeline
30 May 2023
Primary endpoint
20 November 2024
20 November 2024

Quick facts

Lead sponsorGCS Ramsay Santé pour l'Enseignement et la Recherche
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment35
Start date30 May 2023
Primary completion20 November 2024
Estimated completion20 November 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

GCS Ramsay Santé pour l'Enseignement et la Recherche — full company profile →

Who can join

65 and older, any sex, with Aortic Stenosis, Severe. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is implantation of a Pacemaker at 30 days for occurrence of a high-grade conduction disorder per- or post-procedure (yes/no)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Transcatheter Aortic Valve Implantation

Trials testing the same drug.

Other recruiting trials for Aortic Stenosis, Severe

Currently open trials in the same condition.

Other GCS Ramsay Santé pour l'Enseignement et la Recherche trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05714579.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing